Update on the ELIANA trial (VIDEO)

Article

For Contemporary Pediatrics, Dr Bobby Lazzara discusses the latest data on the effectiveness of CAR T-cell therapy from the ELIANA trial, which was presented at the 2018 American Society of Hematology annual meeting in San Diego, California.

For Contemporary Pediatrics, Dr Bobby Lazzara discusses the latest data on the effectiveness of CAR T-cell therapy from the ELIANA trial, which was presented at the 2018 American Society of Hematology annual meeting in San Diego, California.

Recent Videos
Jenna Marcovitz, MA explains how music therapy helps in pediatric care
Peter S. Jensen, MD
Suzanne Hollander, MS, RD, LDN, Senior Clinical Nutrition Specialist, Boston Children's Hospital | Image credit: Boston Children's
Joshua Feder, MD
Zika-based therapy for metastatic neuroblastoma with Tamarah Westmoreland, MD and Joseph Mazar, PhD | Image Credit: © Nemours- © Nemours - stock.adobe.com.
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Related Content
Maternal RSV vaccine data reveal uptake disparities | Image Credit: © Anna - © Anna - stock.adobe.com.

Maternal RSV vaccine data reveal uptake disparities

Morgan Ebert, Managing Editor
May 20th 2025
Article

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Weekly review: Multiple FDA action items, USPSTF recommendation, and more

Weekly review: Multiple FDA action items, USPSTF recommendation, and more

Joshua Fitch, Senior Editor
May 19th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA approves NVX-CoV2705 COVID-19 vaccine | Image credit: Contemporary Pediatrics

FDA approves NVX-CoV2705 COVID-19 vaccine

Joshua Fitch, Senior Editor
May 19th 2025
Article

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.

RSV data highlight age- and condition-specific risks for severe disease in children | Image Credit: © bankrx - © bankrx - stock.adobe.com.

Age, condition-specific risks for severe RSV disease in children

Joshua Fitch, Senior Editor
May 17th 2025
Article

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

© 2025 MJH Life Sciences

All rights reserved.